

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

CXCR4 RABBIT PAB

货号: S221197

产品全名: CXCR4 兔多抗

基因符号 FB22; HM89; LAP3; LCR1; NPYR; WHIM; CD184; LAP-3; LESTR; NPY3R; NPYRL; WHIMS; HSY3RR; NPYY3R; D2S201E

UNIPROT ID: P61073 (Gene Accession - NP_003458)

背景: This gene encodes a CXC chemokine receptor specific for stromal cell-derived factor-1. The protein has 7 transmembrane regions and is located on the cell surface. It acts with the CD4 protein to support HIV entry into cells and is also highly expressed in breast cancer cells. Mutations in this gene have been associated with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.

抗原: Synthetic peptide of human CXCR4

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 25-100; ELISA: 2000-5000

种属反应性: Rabbit


克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification 种属反应性: Human, Mouse, Rat


成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Cancer, Cardiovascular, Metabolism, Neuroscience, Immunology, Stem Cells


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 221197(CXCR4 Antibody) at a dilution of 1/20(Cell membrane)



In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the synthetic peptide and then with 221197(Anti-CXCR4 Antibody) at dilution 1/20.



The image on the left is immunohistochemistry of paraffinembedded Human esophagus cancer tissue using 221197(Anti-CXCR4 Antibody) at a dilution of 1/20.



In comparision with the IHC on the left, the same paraffin-embedded Human esophagus cancer tissue is first treated with synthetic peptide and then with D262693(Anti-CXCR4 Antibody) at dilution 1/20.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010